What is Crizanlizumab: Uses, Dosage, Side Effects and More

Crizanlizumab is a medication specifically designed to help people with sickle cell disease reduce their painful crises. It's given through an IV infusion at a healthcare facility, typically once a month, and works by preventing blood cells from sticking together in your blood vessels.

This targeted treatment represents a significant step forward for sickle cell patients who experience frequent pain episodes. By blocking a specific protein that causes blood cells to clump together, crizanlizumab can help you have fewer painful crises and potentially improve your quality of life.

What is Crizanlizumab?

Crizanlizumab is a monoclonal antibody medication that targets a protein called P-selectin in your blood vessels. Think of P-selectin as a sticky surface that causes blood cells to clump together, which can block blood flow and cause the intense pain associated with sickle cell crises.

The medication is manufactured under the brand name Adakveo and belongs to a class of drugs called selectin blockers. It's specifically engineered to recognize and bind to P-selectin, essentially coating these sticky spots so blood cells can flow more freely through your vessels.

This is considered a specialty medication because it requires careful monitoring and administration in a clinical setting. Your healthcare team will work closely with you to determine if crizanlizumab is the right choice for your specific situation.

What is Crizanlizumab Used For?

Crizanlizumab is primarily used to reduce the frequency of painful vaso-occlusive crises in people with sickle cell disease. These crises happen when sickled blood cells block blood vessels, causing severe pain that can last for hours or even days.

The medication is approved for adults and children 16 years and older who experience recurrent pain crises. You don't need to have a specific number of crises per year to qualify, but your doctor will consider your individual pain history and overall health when deciding if this treatment is appropriate.

While crizanlizumab can significantly reduce crisis frequency, it's important to understand that it may not eliminate all painful episodes. Most people still experience some crises, but they tend to be less frequent and sometimes less severe than before treatment.

How Does Crizanlizumab Work?

Crizanlizumab works by blocking P-selectin, a protein that acts like molecular velcro on the inside of your blood vessels. When P-selectin is active, it causes blood cells, platelets, and other substances to stick to blood vessel walls and to each other.

In sickle cell disease, this sticking process is particularly problematic because your red blood cells are already misshapen and tend to get trapped easily. By blocking P-selectin, crizanlizumab helps prevent this cellular traffic jam from forming in the first place.

This is considered a moderately strong medication in terms of its targeted action, but it works gently over time rather than providing immediate relief. The effects build up gradually, which is why you'll typically need several infusions before experiencing the full benefits.

How Should I Take Crizanlizumab?

Crizanlizumab is given as an intravenous infusion over about 30 minutes in a healthcare facility. You'll receive the medication once every four weeks, and your healthcare team will monitor you during and after each infusion.

Before your infusion, you may be given premedications to help prevent allergic reactions. These might include antihistamines, acetaminophen, or corticosteroids. Your doctor will let you know if you need these additional medications.

You don't need to fast before treatment, and you can eat normally on infusion days. However, it's a good idea to stay well-hydrated by drinking plenty of water before and after your appointment. Some people find it helpful to bring a snack and something to keep them occupied during the infusion.

How Long Should I Take Crizanlizumab For?

Crizanlizumab is typically a long-term treatment that you'll continue as long as it's helping reduce your pain crises and you're not experiencing troublesome side effects. Most people stay on the medication for months or years.

Your doctor will regularly assess how well the treatment is working for you, usually after the first few months of treatment. They'll look at how many pain crises you're having compared to before starting crizanlizumab and monitor for any side effects.

The decision to continue or stop treatment will depend on your individual response and any changes in your overall health. Some people may need to pause treatment temporarily if they develop infections or other health issues, but many can resume once they're feeling better.

What Are the Side Effects of Crizanlizumab?

Like all medications, crizanlizumab can cause side effects, though many people tolerate it well. The most common side effects are generally mild and manageable with proper medical support.

Here are the side effects you might experience, keeping in mind that not everyone will have these reactions:

Common side effects include:

• Nausea and stomach discomfort
• Joint pain or arthralgia
• Back pain
• Fever
• Infusion-related reactions like flushing or mild allergic symptoms

Less common but more serious side effects include:

• Severe allergic reactions during or after infusion
• Increased risk of infections
• Significant changes in blood pressure
• Unusual bleeding or bruising

Rare but serious complications include:

• Anaphylaxis (severe allergic reaction)
• Serious infections that may require hospitalization
• Interference with platelet function leading to bleeding issues

Your healthcare team will monitor you closely during each infusion and will teach you what warning signs to watch for at home. Most side effects are manageable, and the benefits of reduced pain crises often outweigh these risks for many patients.

Who Should Not Take Crizanlizumab?

Crizanlizumab isn't suitable for everyone, and your doctor will carefully evaluate whether it's safe for you based on your medical history and current health status.

You should not receive crizanlizumab if you have a known severe allergy to the medication or any of its components. Your doctor will also be cautious if you have a history of severe allergic reactions to other monoclonal antibody medications.

People with active serious infections may need to wait until the infection is treated before starting crizanlizumab. The medication can potentially interfere with your immune system's ability to fight infections, so timing is important.

Pregnant and breastfeeding women should discuss the risks and benefits carefully with their healthcare provider, as there's limited safety data for these situations. Your doctor will weigh the potential benefits against any possible risks to you and your baby.

Crizanlizumab Brand Name

Crizanlizumab is marketed under the brand name Adakveo by Novartis Pharmaceuticals. This is currently the only brand name available for this medication in the United States.

When you receive your treatment, you'll see Adakveo on the medication label and in your medical records. There are no generic versions of crizanlizumab available at this time, as it's a relatively new medication still under patent protection.

Your insurance coverage and prior authorization requirements will typically refer to both the generic name (crizanlizumab) and the brand name (Adakveo) in their documentation.

Crizanlizumab Alternatives

While crizanlizumab is unique in how it works, there are other medications available to help manage sickle cell disease and reduce pain crises. Your doctor might consider these alternatives if crizanlizumab isn't right for you.

Hydroxyurea is often the first-line treatment for preventing sickle cell crises. It works differently than crizanlizumab by increasing the production of fetal hemoglobin, which helps prevent red blood cells from sickling.

Voxelotor (Oxbryta) is another newer medication that works by increasing the affinity of hemoglobin for oxygen, helping to prevent sickling. L-glutamine (Endari) is an amino acid supplement that may help reduce crisis frequency through different mechanisms.

Your doctor might also recommend combination therapy, using crizanlizumab along with hydroxyurea or other treatments. The choice depends on your specific symptoms, medical history, and how well you've responded to previous treatments.

Is Crizanlizumab Better Than Hydroxyurea?

Crizanlizumab and hydroxyurea work through completely different mechanisms, so comparing them directly isn't always straightforward. Both can be effective at reducing pain crises, but they may work better for different people or in different situations.

Hydroxyurea has been used for decades and has a well-established safety profile, while crizanlizumab is newer with potentially fewer long-term data. However, some people who don't respond well to hydroxyurea may find significant benefit from crizanlizumab.

Many doctors actually use these medications together rather than choosing one over the other. The combination approach can sometimes provide better crisis prevention than either medication alone. Your doctor will consider your individual medical history, previous treatment responses, and personal preferences when making recommendations.